AMH Ovarian Reserve Test Australia: What It Measures

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Reproductive hormone assessment requires individual clinical evaluation. Always consult a qualified healthcare practitioner before making decisions about fertility investigations or treatment.

What Is Anti-Müllerian Hormone?

Anti-Müllerian hormone (AMH) is a glycoprotein produced by the granulosa cells of small antral and pre-antral follicles in the ovary. Unlike most reproductive hormones, AMH secretion is largely independent of the menstrual cycle, it does not surge or trough with oestrogen and progesterone, and it remains relatively stable whether a blood draw is taken on day 2 or day 14. This cycle-independence is one of the features that makes AMH practically useful as a clinical marker: a single blood draw on any day of the cycle produces a result that is broadly comparable across time.

The hormone serves as a proxy for the size of the remaining primordial follicle pool, the ovarian reserve. As women age, the number of follicles in the ovaries declines, and AMH production falls correspondingly. A 35-year-old woman will typically have an AMH level substantially below that of a 25-year-old, even if both have entirely normal reproductive function. This is not pathology; it is physiology.

AMH was originally characterised in male foetal development, where it drives regression of the Müllerian ducts (the embryonic precursors to the uterus, fallopian tubes, and upper vagina). In adult women its role is primarily paracrine, regulating the sensitivity of follicles to FSH and modulating how many follicles are recruited in each cycle.

What AMH Measures: and What It Does Not

This distinction matters enormously, and it is where the clinical conversation most often goes wrong.

AMH measures ovarian reserve: the quantity of remaining follicles. It does not directly measure egg quality, the likelihood of conception in any given cycle, or overall fertility in the sense most people understand the word.

A landmark prospective cohort study published in JAMA in 2017, often called the Steiner study, followed 750 women aged 30–44 who were attempting to conceive naturally. Women with low AMH (indicating diminished ovarian reserve) had no measurable reduction in fecundability, the probability of conceiving per cycle, compared to women with normal AMH. Twelve-cycle cumulative conception rates were statistically similar across AMH categories. The study authors concluded that AMH levels should not be used to counsel women about their natural fertility prospects.¹

This finding is counterintuitive to many, but it has a logical basis. Natural conception requires only one viable egg and one functional tube. Even a woman with very low ovarian reserve still ovulates monthly in most cycles, and that single egg is all that is required. AMH falls before ovulation frequency declines, meaning a low AMH result can precede any actual impairment of monthly ovulation by years.

Where AMH genuinely predicts outcomes is in the context of assisted reproduction. In IVF, the goal is to retrieve multiple eggs in a single stimulation cycle. Women with low AMH produce fewer eggs in response to gonadotrophin stimulation, a phenomenon called poor ovarian response, and this directly affects the number of embryos available for transfer or freezing. A 2022 clinical review confirmed that AMH has well-established utility in predicting ovarian response to stimulation and guiding IVF protocol selection, while emphasising that its predictive value for live birth per cycle remains more limited.²

The practical implication: AMH is most actionable in the IVF context, where it guides stimulation protocol design and cycle planning. In the context of natural conception, a low result is a signal about the future trajectory of reserve, not about present-cycle fertility.

Age-Based Reference Ranges in Australia

Australian laboratories measure AMH in pmol/L (some international references use ng/mL; 1 ng/mL ≈ 7.14 pmol/L). There is no single universal reference range, and values vary slightly between assay platforms, but the following thresholds are broadly used in clinical practice in Australia:

These ranges should be interpreted alongside age because the expected value declines naturally throughout reproductive life. A result of 10 pmol/L at age 28 warrants more attention than the same result at age 42. Some fertility clinics use age-specific percentile charts for this reason, comparing the result against peers of the same age rather than against a flat population cutoff.

It is also worth noting that AMH is relatively stable across the menstrual cycle but can be influenced by hormonal contraception. Women using the combined oral contraceptive pill (COCP) or hormonal IUDs often have suppressed AMH levels; levels typically recover within 2–3 months of cessation. Clinicians interpreting AMH in this context should be aware of recent contraceptive history.

PCOS and Elevated AMH

Polycystic ovary syndrome (PCOS) produces the opposite pattern from diminished ovarian reserve. Rather than too few follicles, women with PCOS have a large cohort of small antral follicles, sometimes several times the number seen in women without PCOS. Because each follicle contributes AMH, total serum AMH is substantially elevated, often two to four times higher than age-matched controls.

AMH levels above 35–45 pmol/L in a reproductive-age woman are strongly associated with polycystic ovarian morphology and, in the right clinical context (menstrual irregularity, androgen excess), support a PCOS diagnosis. Some endocrinologists have proposed AMH as an adjunct or potential replacement diagnostic criterion for PCOS, given the inconsistencies in ultrasound follicle counting across different machines and operators.

However, it is important not to over-interpret an elevated AMH in isolation. A high AMH in a woman with regular cycles, no androgen symptoms, and a normal ultrasound may simply reflect a naturally high follicle count rather than PCOS. As with low results, context governs interpretation.

Women with PCOS who undergo IVF face a different set of risks arising from their AMH elevation. High AMH predicts high ovarian response and elevated risk of ovarian hyperstimulation syndrome (OHSS), an excessive response to gonadotrophin stimulation that can range from mildly uncomfortable to, in rare cases, medically serious. Knowing the AMH ahead of IVF allows the treating team to use lower stimulation doses, antagonist protocols, and other OHSS-mitigation strategies.

Getting an AMH Test in Australia: Cost and Access

AMH testing in Australia is available through both the public and private pathways, but it is not covered by Medicare in most circumstances. The Medicare Benefits Schedule (MBS) does not include AMH as a standard rebatable item for ovarian reserve assessment outside of specific clinical indications such as premature ovarian insufficiency in women under 40.

Out-of-pocket costs through private pathways typically range from approximately $60–$120 AUD, depending on the requesting provider, laboratory, and whether the test is ordered as a standalone or as part of a broader hormone panel. Most fertility clinics include AMH as part of their initial fertility workup, and the cost is usually bundled into the consultation. IVF Australia and other fertility providers list current pricing on their patient information pages.

For women requesting AMH outside of a fertility clinic (for example, as part of general hormone monitoring) a GP referral to a private pathology laboratory (Sonic, Australian Clinical Labs, Healius) is the most common pathway. Some direct-access private blood testing providers also offer AMH without a referral, though results should always be interpreted with clinical support given the nuance involved.

How to Interpret a Low AMH Result

A result below the age-appropriate reference range does not mean infertility. It means the follicle pool is smaller than average for the age group. The practical implications depend heavily on the woman's age, the degree of reduction, and her reproductive plans.

For a 38-year-old woman with an AMH of 4 pmol/L, the trajectory matters: if she wishes to conceive in the near term, discussing IVF sooner rather than later is reasonable, not because natural conception is impossible, but because the reserve is unlikely to increase and IVF response may further diminish over time. For a 32-year-old with the same result, the same logic applies but with a wider time window.

For women considering egg freezing (oocyte cryopreservation), AMH is particularly informative because it predicts how many eggs are likely to be retrieved per stimulation cycle, which directly affects how many cycles may be needed to accumulate a meaningful bank.

A low result also prompts consideration of conditions that accelerate follicle loss: prior ovarian surgery, endometriosis, certain autoimmune conditions, and previous chemotherapy or pelvic radiation. These should be evaluated clinically when AMH is unexpectedly low for age.

Limitations of AMH Testing

Several limitations deserve explicit mention.

AMH does not predict egg quality. The quality of eggs (chromosomal integrity, mitochondrial function) declines with age independently of AMH. Two women with the same AMH level but different ages will have meaningfully different egg quality. This is why IVF success rates are age-stratified rather than AMH-stratified.

A single result is not always definitive. AMH is relatively stable but not perfectly so. Results can vary between labs and between assay platforms. If a result is unexpected, particularly a very low result in a young woman, repeat testing on a different platform or at a different lab is reasonable before making significant decisions.

AMH cannot reliably predict the timing of menopause. While population-level data show a correlation between AMH and time to menopause, the individual predictive accuracy is insufficient to use as a personal forecast. Women with low AMH at 35 do not necessarily reach menopause earlier than women with normal AMH at the same age.

Hormonal contraception suppresses AMH. As noted above, the COCP and progestogen-releasing IUDs can reduce measured AMH by 20–30%. Testing within a few months of stopping contraception may underestimate the true reserve.

Supplements do not raise AMH. Despite claims circulating online, particularly around DHEA and CoQ10, there is no high-quality evidence that any supplement reliably raises serum AMH in women with diminished ovarian reserve. These compounds may have roles in supporting egg quality in specific IVF contexts, but that is a separate clinical question.

AMH in Context: Related Panels Worth Considering

AMH is rarely the only useful marker in a reproductive hormone evaluation. It answers the "how many" question about follicles but does not address ovulatory function, hormonal environment, or cycle quality. The following markers are commonly assessed alongside AMH:

• FSH (Day 2–5): Elevated FSH indicates the pituitary is working harder to recruit follicles, a compensatory signal for diminished reserve. FSH rises as AMH falls, though FSH is more variable cycle-to-cycle.
• Estradiol (Day 2–5): A high early-follicular oestradiol can suppress FSH, masking an elevated FSH result. Interpreted alongside FSH for cycle-day-2 ovarian reserve assessment. See the related guide on estradiol reference ranges and interpretation.
• Progesterone (mid-luteal): Confirms ovulation has occurred. A low mid-luteal progesterone in the context of low AMH raises the question of whether ovulatory cycles are becoming less consistent. Full context on timing and interpretation is covered in the progesterone blood test guide.
• LH and testosterone: Relevant when PCOS is suspected alongside an elevated AMH. An elevated LH:FSH ratio and elevated testosterone or androstenedione support the PCOS diagnosis.

For a broader framework on reading any hormone panel in context, the guide on how to interpret blood test results covers the principles that apply across all biomarkers.

Summary

AMH is a clinically useful but frequently misunderstood test. It measures the quantity of the remaining follicle pool, the ovarian reserve, and does so with reasonable accuracy using a single blood draw on any day of the cycle. In Australia it is measured in pmol/L, is not routinely MBS-rebated, and costs approximately $60–$120 privately.

Its primary clinical value is in predicting response to ovarian stimulation in IVF, where it guides protocol selection and risk stratification for both poor and excessive response. It is also elevated in PCOS, reflecting the large antral follicle cohort characteristic of that condition. What it does not reliably predict is natural fertility cycle-to-cycle: prospective research in women attempting natural conception has found no significant association between AMH levels and monthly fecundability.

A low result should prompt a conversation about reproductive timeline and options, not alarm. A high result in the context of PCOS symptoms warrants appropriate investigation. In either case, AMH is one data point in a clinical picture that includes age, cycle history, partner factors, and individual reproductive goals.